| 1 |
34063867 | Anti-Leukemic Properties of Aplysinopsin Derivative EE-84 Alone and Combined to BH3 Mimetic A-1210477. | 2021 May 21 |
1 |
| 2 |
32486166 | Albendazole-Induced SIRT3 Upregulation Protects Human Leukemia K562 Cells from the Cytotoxicity of MCL1 Suppression. | 2020 May 30 |
2 |
| 3 |
30647404 | Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. | 2019 Jan 15 |
1 |
| 4 |
29348495 | Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells. | 2018 Jan 18 |
1 |
| 5 |
29580266 | Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines. | 2018 Mar 27 |
1 |
| 6 |
30185782 | BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. | 2018 Sep 5 |
1 |
| 7 |
29263915 | Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. | 2017 |
1 |
| 8 |
27765849 | Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. | 2016 Dec |
2 |
| 9 |
27907212 | Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing. | 2016 |
2 |
| 10 |
25590800 | Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). | 2015 Jan 15 |
1 |
| 11 |
26013319 | MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor. | 2015 Aug |
1 |
| 12 |
26565405 | Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). | 2015 Nov 13 |
1 |